Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 5.02
IPCI's Cash to Debt is ranked higher than
70% of the 917 Companies
in the Global Biotechnology industry.

( Industry Median: 20.79 vs. IPCI: 5.02 )
IPCI' s 10-Year Cash to Debt Range
Min: 0.35   Max: No Debt
Current: 5.02

Equity to Asset 0.65
IPCI's Equity to Asset is ranked higher than
72% of the 766 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. IPCI: 0.65 )
IPCI' s 10-Year Equity to Asset Range
Min: -1.36   Max: 1
Current: 0.65

-1.36
1
F-Score: 6
Z-Score: 5.51
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -44.16
IPCI's Operating margin (%) is ranked higher than
74% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -65.07 vs. IPCI: -44.16 )
IPCI' s 10-Year Operating margin (%) Range
Min: -1046100   Max: -414.8
Current: -44.16

-1046100
-414.8
Net-margin (%) -116.32
IPCI's Net-margin (%) is ranked higher than
68% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -70.66 vs. IPCI: -116.32 )
IPCI' s 10-Year Net-margin (%) Range
Min: -914800   Max: -394.86
Current: -116.32

-914800
-394.86
ROE (%) -126.11
IPCI's ROE (%) is ranked higher than
55% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -21.70 vs. IPCI: -126.11 )
IPCI' s 10-Year ROE (%) Range
Min: -6194.62   Max: -22.89
Current: -126.11

-6194.62
-22.89
ROA (%) -82.26
IPCI's ROA (%) is ranked higher than
54% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: -18.92 vs. IPCI: -82.26 )
IPCI' s 10-Year ROA (%) Range
Min: -262.44   Max: -22.22
Current: -82.26

-262.44
-22.22
ROC (Joel Greenblatt) (%) -253.31
IPCI's ROC (Joel Greenblatt) (%) is ranked higher than
71% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: -215.73 vs. IPCI: -253.31 )
IPCI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -104630.77   Max: -553.94
Current: -253.31

-104630.77
-553.94
Revenue Growth (%) -14.90
IPCI's Revenue Growth (%) is ranked higher than
68% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. IPCI: -14.90 )
IPCI' s 10-Year Revenue Growth (%) Range
Min: 0   Max: -13.9
Current: -14.9

EBITDA Growth (%) 2.40
IPCI's EBITDA Growth (%) is ranked higher than
82% of the 626 Companies
in the Global Biotechnology industry.

( Industry Median: -8.10 vs. IPCI: 2.40 )
IPCI' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 46.2
Current: 2.4

0
46.2
EPS Growth (%) 4.90
IPCI's EPS Growth (%) is ranked higher than
84% of the 645 Companies
in the Global Biotechnology industry.

( Industry Median: -10.20 vs. IPCI: 4.90 )
IPCI' s 10-Year EPS Growth (%) Range
Min: 0   Max: 65.3
Current: 4.9

0
65.3
» IPCI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with IPCI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 10.94
IPCI's P/B is ranked higher than
64% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 6.41 vs. IPCI: 10.94 )
IPCI' s 10-Year P/B Range
Min: 6.85   Max: 16.24
Current: 10.94

6.85
16.24
P/S 9.76
IPCI's P/S is ranked higher than
80% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 20.67 vs. IPCI: 9.76 )
IPCI' s 10-Year P/S Range
Min: 7.38   Max: 175
Current: 9.76

7.38
175
EV-to-EBIT -16.04
IPCI's EV-to-EBIT is ranked higher than
70% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. IPCI: -16.04 )
IPCI' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -16.04

Current Ratio 2.46
IPCI's Current Ratio is ranked higher than
63% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 4.31 vs. IPCI: 2.46 )
IPCI' s 10-Year Current Ratio Range
Min: 0.37   Max: 94.99
Current: 2.46

0.37
94.99
Quick Ratio 2.46
IPCI's Quick Ratio is ranked higher than
66% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 3.96 vs. IPCI: 2.46 )
IPCI' s 10-Year Quick Ratio Range
Min: 0.37   Max: 94.99
Current: 2.46

0.37
94.99

Valuation & Return

vs
industry
vs
history
Price/Net Cash 22.57
IPCI's Price/Net Cash is ranked higher than
81% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 190.00 vs. IPCI: 22.57 )
IPCI' s 10-Year Price/Net Cash Range
Min: 0.02   Max: 89
Current: 22.57

0.02
89
Price/Net Current Asset Value 16.41
IPCI's Price/Net Current Asset Value is ranked higher than
81% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 79.32 vs. IPCI: 16.41 )
IPCI' s 10-Year Price/Net Current Asset Value Range
Min: 0.02   Max: 59
Current: 16.41

0.02
59
Price/Tangible Book 10.94
IPCI's Price/Tangible Book is ranked higher than
71% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9.62 vs. IPCI: 10.94 )
IPCI' s 10-Year Price/Tangible Book Range
Min: 0.02   Max: 258
Current: 10.94

0.02
258
Price/Median PS Value 0.17
IPCI's Price/Median PS Value is ranked higher than
99% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 1.97 vs. IPCI: 0.17 )
IPCI' s 10-Year Price/Median PS Value Range
Min: 0.12   Max: 66.96
Current: 0.17

0.12
66.96
Forward Rate of Return (Yacktman) -55.40
IPCI's Forward Rate of Return (Yacktman) is ranked higher than
62% of the 757 Companies
in the Global Biotechnology industry.

( Industry Median: -10.00 vs. IPCI: -55.40 )
IPCI' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0   Max: 0
Current: -55.4

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:I.Canada, I4A.Germany
IntelliPharmaCeutics International, Inc., was incorporated under the Canada Business Corporations Act by certificate and articles of arrangement dated October 22, 2009. The Company is engaged in the research, development, and commercialization of controlled-release and targeted pharmaceutical products. Controlled-release means releasing a drug into the bloodstream or at a target site in the body, over an extended period of time or at predetermined times. The Company's has developed drug delivery technology systems, based on the Hypermatrix platform, that facilitate controlled-release delivery of a range of pharmaceuticals. The Company's technology has been incorporated in drugs manufactured and sold by major pharmaceutical companies. The Company's platform of Hypermatrix drug delivery technologies include, but are not limited to, IntelliFoam, IntelliGITransporter, IntelliMatrix, IntelliOsmotics, IntelliPaste, IntelliPellets, and IntelliShuttle. These technologies provide a range of release profiles, taking into account the physical and chemical characteristics of a drug product, the therapeutic use of the particular drug, and the optimal site for release of the API in the gastrointestinal tract ('GIT'). It has a pipeline of products in various stages of development in therapeutic areas, including neurology, cardiovascular, and gastrointestinal tract, pain, and infection. The Company's competitors include medical technology, pharmaceutical, biotechnology and other companies, universities and research institutions. The research and development, manufacture and marketing of controlled-release pharmaceuticals are subject to regulation by U.S., Canadian and other governmental authorities and agencies.
» More Articles for NAS:IPCI

Headlines

Articles On GuruFocus.com
No related article found.


More From Other Websites
Will IntelliPharmaCeutics (IPCI) Continue to Surge Higher? Sep 16 2014
IntelliPharmaCeutics (IPCI) in Focus: Stock Gains 15.9% Sep 08 2014
Intellipharmaceutics Intl upgraded by Maxim Group Sep 05 2014
Intellipharmaceutics' Oxycodone Program to Prevent Overdose Aug 29 2014
Intellipharmaceutics Augments Its Rexista(TM) Oxycodone Development Program With Novel Overdose... Aug 28 2014
IntelliPharmaCeutics (IPCI): Moving Average Crossover Alert Jul 29 2014
5 Stocks Ready for Breakouts Jul 28 2014
Why Intellipharmaceutics (IPCI) Stock Is Down Today Jul 09 2014
Intellipharmaceutics downgraded to Hold from Buy at Maxim Jul 09 2014
IntelliPharmaCeutics International (IPCI) Crumbles: Stock Plunges by 13.3% Jul 09 2014
Intellipharmaceutics Announces Second Quarter 2014 Results Jul 07 2014
Intellipharmaceutics Files Preliminary Base Shelf Prospectus and Shelf Registration Statement May 20 2014
Intellipharmaceutics files $100M mixed securities shelf May 20 2014
Flamel Technologies SA (FLML) Soars: Stock Up 6.6% Apr 17 2014
Tetraphase Slumps: TTPH Falls 10.3% in Session Apr 15 2014
Catalyst Pharmaceutical Partners Inc. (CPRX) Jumps: Stock Up 8.6% Apr 04 2014
Corcept Therapeutics (CORT) Jumps: Stock Adds 5.4% in Session Mar 31 2014
Can the Rally in IntelliPharmaCeutics (IPCI) Shares Continue? Mar 21 2014
4 Stocks Under to Trade for Breakouts Mar 21 2014
IntelliPharmaCeutics International (IPCI) Soars: Stock Rises 9.1% Mar 21 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK